Reboxetine mesylate

• CAT Number: A000190
• CAS Number: 98769-84-7
• Molecular Formula: C20H27NO6S
• Molecular Weight: 409.497
• Purity: ≥95%
• Synonyms: PNU 155950E
• Target: Neuronal Signaling
• Storage: 3 years -20C powder
• IUPAC Name: (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine;methanesulfonic acid
• InChI: InChI=1S/C19H23NO3.CH4O3S/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18;1-5(2,3)4/h3-11,18-20H,2,12-14H2,1H3;1H3,(H,2,3,4)/t18-,19-;/m1./s1
• InChIKey: CGTZMJIMMUNLQD-STYNFMPRSA-N
• SMILES: CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3.CS(=O)(=O)O

Reboxetine is an antidepressant compound that selectively inhibits norepinephrine uptake for norepinephrine and serotonin transporters. Reboxetine mesylate is a potent and selective inhibitor of SLC6A2 noradrenalin uptake. Reboxetine displays > 1000-fold selectivity over α-adrenoceptors, 5-HT, dopamine, and muscarinic ACh receptors.

Reference

1: Mergui J, Jaworowski S. Risperidone-Induced Nocturnal Enuresis Successfully Treated With Reboxetine. Clin Neuropharmacol. 2016 Mar 17. [Epub ahead of print] PubMed PMID: 26992158.2: Dong C, Zhang JC, Yao W, Ren Q, Yang C, Ma M, Han M, Saito R, Hashimoto K. Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav. 2016 May;144:7-12. doi: 10.1016/j.pbb.2016.02.005. Epub 2016 Feb 15. PubMed PMID: 26892759.3: Witten L, Bastlund JF, Glenthøj BY, Bundgaard C, Steiniger-Brach B, Mørk A, Oranje B. Comparing Pharmacological Modulation of Sensory Gating in Healthy Humans and Rats: The Effects of Reboxetine and Haloperidol. Neuropsychopharmacology. 2016 Jan;41(2):638-45. doi: 10.1038/npp.2015.194. Epub 2015 Jul 1. PubMed PMID: 26129678.4: Bozkurt H, Şahin S. Weight Loss Associated with Reboxetine Use in Adolescents. J Child Adolesc Psychopharmacol. 2016 Feb;26(1):82-3. doi: 10.1089/cap.2015.0199. Epub 2016 Jan 27. PubMed PMID: 26881861.5: Roni MA, Rahman S. Effects of lobeline and reboxetine, fluoxetine, or bupropion combination on depression-like behaviors in mice. Pharmacol Biochem Behav. 2015 Dec;139(Pt A):1-6. doi: 10.1016/j.pbb.2015.10.006. Epub 2015 Oct 9. PubMed PMID: 26455278.6: Popławska M, Wróblewska D, Borowicz KK. Interactions between an antidepressant reboxetine and four classic antiepileptic drugs in the mouse model of myoclonic seizures. Pharmacol Rep. 2015 Dec;67(6):1141-6. doi: 10.1016/j.pharep.2015.04.016. Epub 2015 May 9. PubMed PMID: 26481533.7: Braithwaite R. Reboxetine has no antidepressant effect at all. BMJ. 2015 Nov 3;351:h5842. doi: 10.1136/bmj.h5842. PubMed PMID: 26531816.8: Caudill MM, Hunter AM, Cook IA, Leuchter AF. The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder. Clin EEG Neurosci. 2015 Oct;46(4):277-84. doi: 10.1177/1550059414532443. Epub 2014 Sep 24. PubMed PMID: 25258429.9: Kruchinina AD, Gengin MT. [Effect of reboxetine on activity of carboxypeptidase E in the nerve tissue of rats]. Biomed Khim. 2015 Sep-Oct;61(5):657-60. doi: 10.18097/PBMC20156105657. Russian. PubMed PMID: 26539877.10: Metzger CD, Wiegers M, Walter M, Abler B, Graf H. Local and Global Resting State Activity in the Noradrenergic and Dopaminergic Pathway Modulated by Reboxetine and Amisulpride in Healthy Subjects. Int J Neuropsychopharmacol. 2015 Jul 25;19(2). pii: pyv080. doi: 10.1093/ijnp/pyv080. PubMed PMID: 26209860; PubMed Central PMCID: PMC4772816.11: Ghanizadeh A. A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder. Nord J Psychiatry. 2015 May;69(4):241-8. doi: 10.3109/08039488.2014.972975. Epub 2014 Nov 21. Review. PubMed PMID: 25415763.12: Penmatsa A, Wang KH, Gouaux E. X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine. Nat Struct Mol Biol. 2015 Jun;22(6):506-8. doi: 10.1038/nsmb.3029. Epub 2015 May 11. PubMed PMID: 25961798; PubMed Central PMCID: PMC4608549.13: Yucel A, Yucel N, Ozcan H, Gulec M, Aydin A. Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases. J Clin Psychopharmacol. 2015 Jun;35(3):354-5. doi: 10.1097/JCP.0000000000000301. PubMed PMID: 25822478.14: Gray VC, Hughes RN. Drug-, dose- and sex-dependent effects of chronic fluoxetine, reboxetine and venlafaxine on open-field behavior and spatial memory in rats. Behav Brain Res. 2015 Mar 15;281:43-54. doi: 10.1016/j.bbr.2014.12.023. Epub 2014 Dec 16. PubMed PMID: 25523028.15: Hughes S, Hickey L, Donaldson LF, Lumb BM, Pickering AE. Intrathecal reboxetine suppresses evoked and ongoing neuropathic pain behaviours by restoring spinal noradrenergic inhibitory tone. Pain. 2015 Feb;156(2):328-34. doi: 10.1097/01.j.pain.0000460313.73358.31. PubMed PMID: 25599454.16: Bhagya V, Srikumar BN, Raju TR, Shankaranarayana Rao BS. The selective noradrenergic reuptake inhibitor reboxetine restores spatial learning deficits, biochemical changes, and hippocampal synaptic plasticity in an animal model of depression. J Neurosci Res. 2015 Jan;93(1):104-20. doi: 10.1002/jnr.23473. Epub 2014 Aug 21. PubMed PMID: 25146499.17: Wiles NJ, Fischer K, Cowen P, Nutt D, Peters TJ, Lewis G, White IR. Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial. Psychol Med. 2014 Oct;44(13):2855-66. doi: 10.1017/S0033291714000221. Epub 2014 Mar 3. PubMed PMID: 25065692; PubMed Central PMCID: PMC4131263.18: Graf H, Wiegers M, Metzger CD, Walter M, Grön G, Abler B. Erotic stimulus processing under amisulpride and reboxetine: a placebo-controlled fMRI study in healthy subjects. Int J Neuropsychopharmacol. 2014 Oct 31;18(2). pii: pyu004. doi: 10.1093/ijnp/pyu004. PubMed PMID: 25612894; PubMed Central PMCID: PMC4368880.19: Bruno A, Zoccali R, Bellinghieri PM, Pandolfo G, De Fazio P, Spina E, Muscatello MR. Reboxetine adjuvant therapy in patients with schizophrenia showing a suboptimal response to clozapine: a 12-week, open-label, pilot study. J Clin Psychopharmacol. 2014 Oct;34(5):620-3. doi: 10.1097/JCP.0000000000000196. PubMed PMID: 25118083.20: Usall J, López-Carrilero R, Iniesta R, Roca M, Caballero M, Rodriguez-Jimenez R, Oliveira C, Bernardo M, Corripio I, Sindreu SD, González Piqueras JC, Felipe AE, Fernandez de Corres B, Ibáñez A, Huerta R; Abordaje Síntomas Negativos Esquizofrenia Group. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. J Clin Psychiatry. 2014 Jun;75(6):608-15. doi: 10.4088/JCP.13m08551. PubMed PMID: 25004184.